Interaction of a sulfhydryl analogue of vasoactive intestinal peptide (VIP) with murine lymphocytes.
Ottaway
C A
CA
Department of Medicine, University of Toronto, Ontario, Canada.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D002460:Cell Line; D003208:Concanavalin A / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D020109:Devazepide; D008198:Lymph Nodes / Q000166:cytology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008643:Mesentery / Q000166:cytology / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008934:Mitogens / Q000494:pharmacology; D018005:Receptors, Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors / Q000187:drug effects*; D014660:Vasoactive Intestinal Peptide / Q000031:analogs & derivatives* / Q000494:pharmacology
D001570:Benzodiazepinones; D008934:Mitogens; D018005:Receptors, Vasoactive Intestinal Peptide; C097232:vasoactive intestinal peptide, Cys(2)-; C048507:vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-; D003208:Concanavalin A; D014660:Vasoactive Intestinal Peptide; D000242:Cyclic AMP; D020109:Devazepide; D015056:1-Methyl-3-isobutylxanthine